ReviewFrontiers in medicine2025
Combined pulmonary fibrosis and emphysema: a narrative review.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined pulmonary fibrosis and emphysema (CPFE) is defined as a clinical-radiological-physiological syndrome characterized by upper-lobe emphysema and fibrosis predominantly in the lower lobes. The diagnosis of CPFE remains challenging due to the opposing pathophysiological effects of emphysema and fibrosis, which can mask their characteristic clinical and imaging features. Although an international committee proposed standardized terminology for CPFE in 2022, uniform diagnostic criteria and optimal management strategies have not yet been established. Patients with CPFE exhibit reduced overall survival and higher mortality compared to those with chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF). This may be due to increased disease severity, as assessed by CT findings (the extent of fibrosis and emphysema), advanced age, and associated complications such as lung cancer, acute exacerbations, and pulmonary arterial hypertension. This narrative review synthesizes the literature on CPFE from 1990 to 2024, covering its historical background, epidemiology, pathogenesis, clinical presentation, diagnostic features (imaging and pulmonary function), disease course (diagnosis, prognosis, complications), and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.